002907.SZ
华森制药
SZSE · Healthcare · C 制造业 · CN
CNY 14.31
+0.35%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
31.2x
Market Cap
CNY 5.98B
MomentumView details →
1D Return
+0.35%
YTD Return
−2.16%
RSI (14)
49.0
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
31.2x
Market Cap
CNY 5.98B
RSI (14)
49.0
MomentumView details →
1D Return
+0.35%
YTD Return
−2.16%
Similar companies
Latest newsMore news →
Huasen Pharmaceutical received a drug re-registration approval notice from the Chongqing Medical Products Administration for its injection of ethylenediamine diaceturate (0.2g, 0.4g), valid until February 20, 2032.11d agoHuasen Pharmaceutical proposed a cash dividend of 0.35 yuan per 10 shares (tax included) based on total share capital of 418 million shares as of June 30, 2026, with no bonus shares or capital reserve conversion.16d agoHuasen Pharmaceutical announced its first-half 2026 results: revenue of 414 million yuan, down 6.42% year-on-year; net profit attributable to shareholders of 62.98 million yuan, up 16.74% year-on-year.16d ago